Allogeneic stem cell transplantation for autoimmune diseases: Nonmyeloablative conditioning regimens

Y. Oyama*, A. E. Traynor, W. Barr, Richard K Burt

*Corresponding author for this work

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that further study of autologous HSCT especially under phase III design is warranted. However, the ultimate goal of HSCT is cure of otherwise incurable autoimmune diseases. For this reason, allogeneic HSCT in carefully selected high-risk patients with autoimmune diseases using strategies to minimize both regimen-related toxicity and graft-versus-host disease (GVHD) is ongoing at Northwestern University and will be reviewed briefly.

Original languageEnglish (US)
Pages (from-to)S81-S83
JournalBone Marrow Transplantation
Volume32
DOIs
StatePublished - Jan 1 2003

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Allogeneic stem cell transplantation for autoimmune diseases: Nonmyeloablative conditioning regimens'. Together they form a unique fingerprint.

  • Cite this